Skip to main content

Genetic Anomaly of Chronic Lymphocytic Leukemia

From the 2021 Joint Annual Meeting (recorded 6/28/2021)
Presented by Susan Leclair, Ph.D.

This presentation will evaluate the clinical importance of the expanding number of genetic mutations found in patient with CLL and their prognostic or therapy implications.

LEARNING OBJECTIVES
At the conclusion of this presentation, participants will be able to:

  • Explain the function aberrations in the top 5 mutations
  • Rank the genetic aberrations with severity of disease
  • Associate the types of therapies and their chance of success

CE ACCREDITATION
ASCLS is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. One (1) P.A.C.E. ® contact hour and one (1) Florida credit hour in the area of General (Hematology) will be awarded to participants. ASCLS P.A.C.E.® is accepted by the ASCP/ASCLS/AGT Board of Certification and all states, including Florida and California, as an approved provider of continuing education for recertification and licensure. ASCLS is an approved provider with CE Broker for Florida licensees.

LEVEL OF INSTRUCTION
This Intermediate-level program is appropriate for laboratory professionals working in clinical, public health and academic settings.